Percutaneous tumor ablation versus partial nephrectomy for small renal mass: the impact of histologic variant and tumor size.


Journal

Minerva urology and nephrology
ISSN: 2724-6442
Titre abrégé: Minerva Urol Nephrol
Pays: Italy
ID NLM: 101777299

Informations de publication

Date de publication:
10 2021
Historique:
pubmed: 2 12 2020
medline: 15 12 2021
entrez: 1 12 2020
Statut: ppublish

Résumé

The aim, of this study was to investigate recurrence rates in patients with T1 renal cell carcinoma (RCC) undergone partial nephrectomy (PN), radiofrequency ablation (RFA) or cryoablation (Cryo). We retrospectively evaluated data from 665 (81.4%), 68 (8.3%) and 83 (10.3%) patients who underwent PN, RFA and Cryo, respectively. Kaplan-Meier curves depict recurrence-free survival (RFS) rates in the overall population and after stratifying according to tumor's histology (namely, clear cell RCC and non-clear RCC) and size (namely <2 cm and 2-4 cm). Multivariable Cox regression model was used to identify predictors of recurrence. Cumulative-incidence plots evaluated disease recurrence and other causes of mortality (OCM). Patients referred to PN experienced higher RFS rate compared to those treated with RFA and Cryo at 60-month in the overall population (96.4% vs. 79.4% vs. 87.8%), in patients with clear cell RCC (93.3% vs. 75% vs. 80.4%) and in those with tumor of 2-4 cm (97.3% vs. 78% and 84.4%; all P≤0.01). In patients with non-clear cell RCC and with tumor <2cm, PN showed higher RFS rate at 60-month as compared to RFA (97.9% vs. 84.4% and 95.1% vs. 78.1%, respectively: all P≤0.02). At multi-variate analysis, ablative techniques (RFA [HR=4.03] and Cryo [HR=3.86]) were independent predictors of recurrence (all P<0.03). At competing risks analysis, recurrence rate and OCM were 7.3% and 1.3% vs. 25% and 7.2% vs. 19.9% and 19.9% for PN, RFA and Cryo, respectively. PN and Cryo showed similar RFS rates in patients with non-clear cell RCC and with renal mass <2cm.

Sections du résumé

BACKGROUND
The aim, of this study was to investigate recurrence rates in patients with T1 renal cell carcinoma (RCC) undergone partial nephrectomy (PN), radiofrequency ablation (RFA) or cryoablation (Cryo).
METHODS
We retrospectively evaluated data from 665 (81.4%), 68 (8.3%) and 83 (10.3%) patients who underwent PN, RFA and Cryo, respectively. Kaplan-Meier curves depict recurrence-free survival (RFS) rates in the overall population and after stratifying according to tumor's histology (namely, clear cell RCC and non-clear RCC) and size (namely <2 cm and 2-4 cm). Multivariable Cox regression model was used to identify predictors of recurrence. Cumulative-incidence plots evaluated disease recurrence and other causes of mortality (OCM).
RESULTS
Patients referred to PN experienced higher RFS rate compared to those treated with RFA and Cryo at 60-month in the overall population (96.4% vs. 79.4% vs. 87.8%), in patients with clear cell RCC (93.3% vs. 75% vs. 80.4%) and in those with tumor of 2-4 cm (97.3% vs. 78% and 84.4%; all P≤0.01). In patients with non-clear cell RCC and with tumor <2cm, PN showed higher RFS rate at 60-month as compared to RFA (97.9% vs. 84.4% and 95.1% vs. 78.1%, respectively: all P≤0.02). At multi-variate analysis, ablative techniques (RFA [HR=4.03] and Cryo [HR=3.86]) were independent predictors of recurrence (all P<0.03). At competing risks analysis, recurrence rate and OCM were 7.3% and 1.3% vs. 25% and 7.2% vs. 19.9% and 19.9% for PN, RFA and Cryo, respectively.
CONCLUSIONS
PN and Cryo showed similar RFS rates in patients with non-clear cell RCC and with renal mass <2cm.

Identifiants

pubmed: 33256358
pii: S0393-2249.20.03983-1
doi: 10.23736/S2724-6051.20.03983-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

581-590

Auteurs

Lorenzo Bianchi (L)

Division of Urology, Department of Urology, IRCCS University Hospital of Bologna, Bologna, Italy - lorenzo.bianchi3@gmail.com.
University of Bologna, Bologna, Italy - lorenzo.bianchi3@gmail.com.

Federico Mineo Bianchi (F)

Division of Urology, Department of Urology, IRCCS University Hospital of Bologna, Bologna, Italy.

Francesco Chessa (F)

Division of Urology, Department of Urology, IRCCS University Hospital of Bologna, Bologna, Italy.
University of Bologna, Bologna, Italy.

Umberto Barbaresi (U)

Division of Urology, Department of Urology, IRCCS University Hospital of Bologna, Bologna, Italy.

Carlo Casablanca (C)

Division of Urology, Department of Urology, IRCCS University Hospital of Bologna, Bologna, Italy.

Pietro Piazza (P)

Division of Urology, Department of Urology, IRCCS University Hospital of Bologna, Bologna, Italy.

Angelo Mottaran (A)

Division of Urology, Department of Urology, IRCCS University Hospital of Bologna, Bologna, Italy.

Matteo Droghetti (M)

Division of Urology, Department of Urology, IRCCS University Hospital of Bologna, Bologna, Italy.

Carlo Roveroni (C)

Division of Urology, Department of Urology, IRCCS University Hospital of Bologna, Bologna, Italy.

Eleonora Balestrazzi (E)

Division of Urology, Department of Urology, IRCCS University Hospital of Bologna, Bologna, Italy.

Giorgio Gentile (G)

Division of Urology, Department of Urology, IRCCS University Hospital of Bologna, Bologna, Italy.

Caterina Gaudiano (C)

Division of Urology, Department of Urology, IRCCS University Hospital of Bologna, Bologna, Italy.

Alessandro Bertaccini (A)

Division of Urology, Department of Urology, IRCCS University Hospital of Bologna, Bologna, Italy.
University of Bologna, Bologna, Italy.

Emanuela Marcelli (E)

University of Bologna, Bologna, Italy.

Angelo Porreca (A)

Department of Radiology, IRCCS University Hospital of Bologna, Bologna, Italy.

Bernardino DE Concilio (B)

Department of Urology, San Bassiano Hospital, Bassano del Grappa, Vicenza, Italy.

Carla Serra (C)

Unit of Interventional Ultrasound, Department of Organ Failure and Transplantations, Sant'Orsola-Malpighi University Hospital, University of Bologna, Bologna, Italy.

Antonio Celia (A)

Department of Urology, San Bassiano Hospital, Bassano del Grappa, Vicenza, Italy.

Eugenio Brunocilla (E)

Division of Urology, Department of Urology, IRCCS University Hospital of Bologna, Bologna, Italy.
University of Bologna, Bologna, Italy.

Riccardo Schiavina (R)

Division of Urology, Department of Urology, IRCCS University Hospital of Bologna, Bologna, Italy.
University of Bologna, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH